JP7265537B2 - Ｒａｄ５１阻害剤 - Google Patents
Ｒａｄ５１阻害剤 Download PDFInfo
- Publication number
- JP7265537B2 JP7265537B2 JP2020514206A JP2020514206A JP7265537B2 JP 7265537 B2 JP7265537 B2 JP 7265537B2 JP 2020514206 A JP2020514206 A JP 2020514206A JP 2020514206 A JP2020514206 A JP 2020514206A JP 7265537 B2 JP7265537 B2 JP 7265537B2
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- group
- halogen
- groups selected
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003112 inhibitor Substances 0.000 title claims description 30
- 108010068097 Rad51 Recombinase Proteins 0.000 title description 33
- 102000001195 RAD51 Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 258
- -1 —OH Chemical group 0.000 claims description 200
- 239000000203 mixture Substances 0.000 claims description 157
- 229910052736 halogen Inorganic materials 0.000 claims description 152
- 150000003839 salts Chemical class 0.000 claims description 138
- 150000002367 halogens Chemical class 0.000 claims description 119
- 238000000034 method Methods 0.000 claims description 98
- 125000002950 monocyclic group Chemical group 0.000 claims description 98
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 96
- 102100022433 Single-stranded DNA cytosine deaminase Human genes 0.000 claims description 92
- 101710143275 Single-stranded DNA cytosine deaminase Proteins 0.000 claims description 88
- 210000004027 cell Anatomy 0.000 claims description 79
- 206010028980 Neoplasm Diseases 0.000 claims description 78
- 125000001072 heteroaryl group Chemical group 0.000 claims description 67
- 201000011510 cancer Diseases 0.000 claims description 66
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 60
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 58
- 125000000623 heterocyclic group Chemical group 0.000 claims description 54
- 125000000217 alkyl group Chemical group 0.000 claims description 52
- 125000004970 halomethyl group Chemical group 0.000 claims description 52
- 108090000623 proteins and genes Proteins 0.000 claims description 49
- 239000008194 pharmaceutical composition Substances 0.000 claims description 41
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 40
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 38
- 102000004190 Enzymes Human genes 0.000 claims description 35
- 108090000790 Enzymes Proteins 0.000 claims description 35
- 230000035772 mutation Effects 0.000 claims description 32
- 238000010442 DNA editing Methods 0.000 claims description 31
- 108020004414 DNA Proteins 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 claims description 24
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 claims description 24
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 24
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 229910052760 oxygen Inorganic materials 0.000 claims description 23
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 19
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 18
- 230000001363 autoimmune Effects 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 208000023275 Autoimmune disease Diseases 0.000 claims description 16
- 206010025323 Lymphomas Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 16
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 15
- 101710183280 Topoisomerase Proteins 0.000 claims description 15
- 208000032839 leukemia Diseases 0.000 claims description 15
- 125000003566 oxetanyl group Chemical group 0.000 claims description 14
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 13
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 13
- 208000011580 syndromic disease Diseases 0.000 claims description 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 12
- 201000009030 Carcinoma Diseases 0.000 claims description 12
- 206010009944 Colon cancer Diseases 0.000 claims description 12
- 208000029742 colonic neoplasm Diseases 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 230000033616 DNA repair Effects 0.000 claims description 11
- 206010061598 Immunodeficiency Diseases 0.000 claims description 11
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 11
- 102000002689 Toll-like receptor Human genes 0.000 claims description 11
- 108020000411 Toll-like receptor Proteins 0.000 claims description 11
- 206010017758 gastric cancer Diseases 0.000 claims description 11
- 201000011549 stomach cancer Diseases 0.000 claims description 11
- 230000007812 deficiency Effects 0.000 claims description 10
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 claims description 10
- 206010025135 lupus erythematosus Diseases 0.000 claims description 10
- 230000004770 neurodegeneration Effects 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims description 9
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 9
- 206010039491 Sarcoma Diseases 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 9
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims description 9
- 230000007813 immunodeficiency Effects 0.000 claims description 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 9
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 9
- 230000028617 response to DNA damage stimulus Effects 0.000 claims description 9
- 239000012623 DNA damaging agent Substances 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 125000002393 azetidinyl group Chemical group 0.000 claims description 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 claims description 8
- 125000005072 dihydrothiopyranyl group Chemical group S1C(CCC=C1)* 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 230000002757 inflammatory effect Effects 0.000 claims description 8
- 201000002313 intestinal cancer Diseases 0.000 claims description 8
- 125000002757 morpholinyl group Chemical group 0.000 claims description 8
- 125000004193 piperazinyl group Chemical group 0.000 claims description 8
- 125000003386 piperidinyl group Chemical group 0.000 claims description 8
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 8
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims description 8
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 8
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 7
- 208000034578 Multiple myelomas Diseases 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 7
- 229940127089 cytotoxic agent Drugs 0.000 claims description 7
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 230000002519 immonomodulatory effect Effects 0.000 claims description 7
- 208000010626 plasma cell neoplasm Diseases 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 claims description 6
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 claims description 6
- 108010044091 Globulins Proteins 0.000 claims description 6
- 102000006395 Globulins Human genes 0.000 claims description 6
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 6
- 208000027747 Kennedy disease Diseases 0.000 claims description 6
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 claims description 6
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims description 6
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 208000033182 PLCG2-associated antibody deficiency and immune dysregulation Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims description 6
- 201000003620 Spinocerebellar ataxia type 6 Diseases 0.000 claims description 6
- 201000003629 Spinocerebellar ataxia type 8 Diseases 0.000 claims description 6
- 208000016349 X-linked agammaglobulinemia Diseases 0.000 claims description 6
- 208000033779 X-linked lymphoproliferative disease Diseases 0.000 claims description 6
- 208000016532 chronic granulomatous disease Diseases 0.000 claims description 6
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 6
- 230000002950 deficient Effects 0.000 claims description 6
- 208000024908 graft versus host disease Diseases 0.000 claims description 6
- 230000000521 hyperimmunizing effect Effects 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 201000008383 nephritis Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 claims description 6
- 201000003594 spinocerebellar ataxia type 12 Diseases 0.000 claims description 6
- 201000003570 spinocerebellar ataxia type 17 Diseases 0.000 claims description 6
- 201000003632 spinocerebellar ataxia type 7 Diseases 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims description 6
- LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1h-imidazole Chemical compound C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 claims description 5
- 208000008190 Agammaglobulinemia Diseases 0.000 claims description 5
- 102000007370 Ataxin2 Human genes 0.000 claims description 5
- 108010032951 Ataxin2 Proteins 0.000 claims description 5
- 208000004736 B-Cell Leukemia Diseases 0.000 claims description 5
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 206010014733 Endometrial cancer Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims description 5
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 201000003622 Spinocerebellar ataxia type 2 Diseases 0.000 claims description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 5
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 5
- 230000005865 ionizing radiation Effects 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 125000000466 oxiranyl group Chemical group 0.000 claims description 5
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 5
- 125000005958 tetrahydrothienyl group Chemical group 0.000 claims description 5
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims description 5
- 201000002510 thyroid cancer Diseases 0.000 claims description 5
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
- HXFLZWAZSSPLCO-UHFFFAOYSA-N 6,6-dimethylbicyclo[3.1.1]heptyl Chemical group C1[C-]2C([CH2+])([CH2-])[C+]1CCC2 HXFLZWAZSSPLCO-UHFFFAOYSA-N 0.000 claims description 4
- 108010004483 APOBEC-3G Deaminase Proteins 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000023611 Burkitt leukaemia Diseases 0.000 claims description 4
- 102100040399 C->U-editing enzyme APOBEC-2 Human genes 0.000 claims description 4
- 102100040263 DNA dC->dU-editing enzyme APOBEC-3A Human genes 0.000 claims description 4
- 102100040261 DNA dC->dU-editing enzyme APOBEC-3C Human genes 0.000 claims description 4
- 102100040264 DNA dC->dU-editing enzyme APOBEC-3D Human genes 0.000 claims description 4
- 102100040266 DNA dC->dU-editing enzyme APOBEC-3F Human genes 0.000 claims description 4
- 102100038076 DNA dC->dU-editing enzyme APOBEC-3G Human genes 0.000 claims description 4
- 102100038050 DNA dC->dU-editing enzyme APOBEC-3H Human genes 0.000 claims description 4
- 101710082737 DNA dC->dU-editing enzyme APOBEC-3H Proteins 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
- 206010073073 Hepatobiliary cancer Diseases 0.000 claims description 4
- 101000964322 Homo sapiens C->U-editing enzyme APOBEC-2 Proteins 0.000 claims description 4
- 101000964378 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3A Proteins 0.000 claims description 4
- 101000964383 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3C Proteins 0.000 claims description 4
- 101000964382 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3D Proteins 0.000 claims description 4
- 101000964377 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3F Proteins 0.000 claims description 4
- 101000800426 Homo sapiens Putative C->U-editing enzyme APOBEC-4 Proteins 0.000 claims description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000007452 Plasmacytoma Diseases 0.000 claims description 4
- 102100033091 Putative C->U-editing enzyme APOBEC-4 Human genes 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims description 4
- 206010046392 Ureteric cancer Diseases 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 210000000601 blood cell Anatomy 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 201000003444 follicular lymphoma Diseases 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 claims description 4
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 208000031223 plasma cell leukemia Diseases 0.000 claims description 4
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 230000006798 recombination Effects 0.000 claims description 4
- 238000005215 recombination Methods 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 3
- 125000005960 1,4-diazepanyl group Chemical group 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 206010003694 Atrophy Diseases 0.000 claims description 3
- 208000030767 Autoimmune encephalitis Diseases 0.000 claims description 3
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims description 3
- 208000017392 BENTA disease Diseases 0.000 claims description 3
- 208000023514 Barrett esophagus Diseases 0.000 claims description 3
- 208000023665 Barrett oesophagus Diseases 0.000 claims description 3
- 206010004593 Bile duct cancer Diseases 0.000 claims description 3
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 claims description 3
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims description 3
- 206010062746 Carditis Diseases 0.000 claims description 3
- 108090000538 Caspase-8 Proteins 0.000 claims description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 3
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 3
- 208000015943 Coeliac disease Diseases 0.000 claims description 3
- 206010010099 Combined immunodeficiency Diseases 0.000 claims description 3
- 206010010356 Congenital anomaly Diseases 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 3
- 102100024350 Dedicator of cytokinesis protein 8 Human genes 0.000 claims description 3
- 201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 claims description 3
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims description 3
- 208000001914 Fragile X syndrome Diseases 0.000 claims description 3
- 208000000259 GATA2 Deficiency Diseases 0.000 claims description 3
- 208000022140 GATA2 deficiency with susceptibility to MDS/AML Diseases 0.000 claims description 3
- 208000007882 Gastritis Diseases 0.000 claims description 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 3
- 101001052946 Homo sapiens Dedicator of cytokinesis protein 8 Proteins 0.000 claims description 3
- 101001017764 Homo sapiens Lipopolysaccharide-responsive and beige-like anchor protein Proteins 0.000 claims description 3
- 101000828537 Homo sapiens Synaptic functional regulator FMR1 Proteins 0.000 claims description 3
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 102100033353 Lipopolysaccharide-responsive and beige-like anchor protein Human genes 0.000 claims description 3
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 3
- 201000003791 MALT lymphoma Diseases 0.000 claims description 3
- 208000036626 Mental retardation Diseases 0.000 claims description 3
- 208000009525 Myocarditis Diseases 0.000 claims description 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 3
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 102100023532 Synaptic functional regulator FMR1 Human genes 0.000 claims description 3
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 claims description 3
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 3
- 208000026309 X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia Diseases 0.000 claims description 3
- 201000006722 X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection, and neoplasia Diseases 0.000 claims description 3
- 230000037444 atrophy Effects 0.000 claims description 3
- 201000004988 autoimmune vasculitis Diseases 0.000 claims description 3
- 125000003725 azepanyl group Chemical group 0.000 claims description 3
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 3
- 229940022399 cancer vaccine Drugs 0.000 claims description 3
- 238000009566 cancer vaccine Methods 0.000 claims description 3
- 210000003591 cerebellar nuclei Anatomy 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 3
- 206010009887 colitis Diseases 0.000 claims description 3
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 125000005959 diazepanyl group Chemical group 0.000 claims description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 3
- 230000013595 glycosylation Effects 0.000 claims description 3
- 238000006206 glycosylation reaction Methods 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 210000002865 immune cell Anatomy 0.000 claims description 3
- 208000014165 immunodeficiency 21 Diseases 0.000 claims description 3
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 3
- 208000021646 inflammation of heart layer Diseases 0.000 claims description 3
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 3
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 238000011127 radiochemotherapy Methods 0.000 claims description 3
- 208000011834 subacute cutaneous lupus erythematosus Diseases 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 125000005888 tetrahydroindolyl group Chemical group 0.000 claims description 3
- 108010029988 AICDA (activation-induced cytidine deaminase) Proteins 0.000 claims description 2
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 2
- 208000000260 Warts Diseases 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 201000010153 skin papilloma Diseases 0.000 claims description 2
- 201000002314 small intestine cancer Diseases 0.000 claims description 2
- 102100026548 Caspase-8 Human genes 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 161
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 145
- 238000005481 NMR spectroscopy Methods 0.000 description 108
- 238000007429 general method Methods 0.000 description 101
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 87
- 230000015572 biosynthetic process Effects 0.000 description 69
- 238000003786 synthesis reaction Methods 0.000 description 67
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 66
- 235000019439 ethyl acetate Nutrition 0.000 description 58
- 239000007787 solid Substances 0.000 description 53
- 239000000243 solution Substances 0.000 description 46
- 239000011734 sodium Substances 0.000 description 42
- 239000000543 intermediate Substances 0.000 description 41
- 125000005843 halogen group Chemical group 0.000 description 39
- 239000003208 petroleum Substances 0.000 description 33
- 102000002490 Rad51 Recombinase Human genes 0.000 description 32
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 25
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 25
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 24
- 239000012044 organic layer Substances 0.000 description 23
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 229910004298 SiO 2 Inorganic materials 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 230000005778 DNA damage Effects 0.000 description 18
- 231100000277 DNA damage Toxicity 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 239000007832 Na2SO4 Substances 0.000 description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 18
- 230000003211 malignant effect Effects 0.000 description 18
- 229920006395 saturated elastomer Polymers 0.000 description 18
- 229910052938 sodium sulfate Inorganic materials 0.000 description 18
- 235000011152 sodium sulphate Nutrition 0.000 description 18
- 125000001424 substituent group Chemical group 0.000 description 18
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 18
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 16
- 238000004440 column chromatography Methods 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 230000005782 double-strand break Effects 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- 238000002953 preparative HPLC Methods 0.000 description 14
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 description 13
- 108700031745 MutS Homolog 2 Proteins 0.000 description 13
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 13
- 230000033607 mismatch repair Effects 0.000 description 13
- 238000012746 preparative thin layer chromatography Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 230000030833 cell death Effects 0.000 description 12
- 125000004093 cyano group Chemical group *C#N 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 230000008439 repair process Effects 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 9
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 9
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000004808 supercritical fluid chromatography Methods 0.000 description 9
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- 201000005027 Lynch syndrome Diseases 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical compound C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
- OVPLZYJGTGDFNB-UHFFFAOYSA-N propan-2-yl carbamate Chemical compound CC(C)OC(N)=O OVPLZYJGTGDFNB-UHFFFAOYSA-N 0.000 description 8
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 206010051922 Hereditary non-polyposis colorectal cancer syndrome Diseases 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 208000009956 adenocarcinoma Diseases 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 125000001309 chloro group Chemical group Cl* 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 239000012299 nitrogen atmosphere Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 230000000405 serological effect Effects 0.000 description 7
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102100039793 E3 ubiquitin-protein ligase RAG1 Human genes 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 101000744443 Homo sapiens E3 ubiquitin-protein ligase RAG1 Proteins 0.000 description 6
- 102000046060 MutS Homolog 3 Human genes 0.000 description 6
- 108700024836 MutS Homolog 3 Proteins 0.000 description 6
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- LEXMZVRWMSPGIV-UHFFFAOYSA-N [3-(tert-butylsulfamoyl)-4-[2-[4-(propan-2-yloxycarbonylamino)cyclohexyl]-1,3-thiazol-5-yl]phenyl]carbamic acid Chemical compound CC(C)OC(=O)NC1CCC(CC1)c1ncc(s1)-c1ccc(NC(O)=O)cc1S(=O)(=O)NC(C)(C)C LEXMZVRWMSPGIV-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 230000012361 double-strand break repair Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000002744 homologous recombination Methods 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000005783 single-strand break Effects 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 229940124530 sulfonamide Drugs 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 101100395211 Trichoderma harzianum his3 gene Proteins 0.000 description 5
- 108010032099 V(D)J recombination activating protein 2 Proteins 0.000 description 5
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 231100000221 frame shift mutation induction Toxicity 0.000 description 5
- 230000037433 frameshift Effects 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- RKEYKDXXZCICFZ-UHFFFAOYSA-N 5-hydroxypipecolic acid Chemical compound OC1CCC(C(O)=O)NC1 RKEYKDXXZCICFZ-UHFFFAOYSA-N 0.000 description 4
- WNLCRBMIFGIKSW-LJGSYFOKSA-N BrC1=CN=C(S1)[C@@H]1CC[C@H](CC1)N Chemical compound BrC1=CN=C(S1)[C@@H]1CC[C@H](CC1)N WNLCRBMIFGIKSW-LJGSYFOKSA-N 0.000 description 4
- 102100028843 DNA mismatch repair protein Mlh1 Human genes 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102000008071 Mismatch Repair Endonuclease PMS2 Human genes 0.000 description 4
- 108010074346 Mismatch Repair Endonuclease PMS2 Proteins 0.000 description 4
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- GZXAGKFOPCQJLV-UHFFFAOYSA-N [4-[5-[4-(benzylcarbamoylamino)-2-(tert-butylsulfamoyl)phenyl]-1,3-thiazol-2-yl]cyclohexyl]carbamic acid Chemical compound CC(C)(C)NS(=O)(=O)c1cc(NC(=O)NCc2ccccc2)ccc1-c1cnc(s1)C1CCC(CC1)NC(O)=O GZXAGKFOPCQJLV-UHFFFAOYSA-N 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 150000003840 hydrochlorides Chemical class 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000000869 mutational effect Effects 0.000 description 4
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- OGKGGBNPVRGQQN-UHFFFAOYSA-N 2-bromo-5-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(Br)C(S(Cl)(=O)=O)=C1 OGKGGBNPVRGQQN-UHFFFAOYSA-N 0.000 description 3
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 208000035900 Autoimmune polyendocrinopathy type 1 Diseases 0.000 description 3
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 3
- 102100022976 B-cell lymphoma/leukemia 11A Human genes 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 3
- 208000005243 Chondrosarcoma Diseases 0.000 description 3
- 208000037051 Chromosomal Instability Diseases 0.000 description 3
- 102100025877 Complement component C1q receptor Human genes 0.000 description 3
- 102100027829 DNA repair protein XRCC3 Human genes 0.000 description 3
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 3
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 3
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 3
- 101000903703 Homo sapiens B-cell lymphoma/leukemia 11A Proteins 0.000 description 3
- 101000933665 Homo sapiens Complement component C1q receptor Proteins 0.000 description 3
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 description 3
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 3
- 101000601724 Homo sapiens Paired box protein Pax-5 Proteins 0.000 description 3
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 3
- XSQDAFWQWINGDK-UHFFFAOYSA-N N-[4-(2-bromo-1,3-thiazol-5-yl)-3-(tert-butylsulfamoyl)phenyl]acetamide Chemical compound BrC=1SC(=CN=1)C1=C(C=C(C=C1)NC(C)=O)S(NC(C)(C)C)(=O)=O XSQDAFWQWINGDK-UHFFFAOYSA-N 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 102100037504 Paired box protein Pax-5 Human genes 0.000 description 3
- 238000003559 RNA-seq method Methods 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 3
- 108010074310 X-ray repair cross complementing protein 3 Proteins 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 201000009771 autoimmune polyendocrine syndrome type 1 Diseases 0.000 description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229940127573 compound 38 Drugs 0.000 description 3
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229960004961 mechlorethamine Drugs 0.000 description 3
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 208000025113 myeloid leukemia Diseases 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- RGBHHBUEOZAGDE-UHFFFAOYSA-N propan-2-yl N-[4-(2-bromo-1,3-thiazol-5-yl)-3-(tert-butylsulfamoyl)phenyl]carbamate Chemical compound BrC=1SC(=CN=1)C1=C(C=C(C=C1)NC(OC(C)C)=O)S(NC(C)(C)C)(=O)=O RGBHHBUEOZAGDE-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- OWALAMKTKVXDJL-LTHGFNDWSA-N (3R,4R,5R)-2-(6-amino-7H-purin-2-yl)-3-fluorooxane-3,4,5-triol Chemical compound N=1C=2N=CNC=2C(N)=NC=1C1OC[C@@H](O)[C@@H](O)[C@@]1(O)F OWALAMKTKVXDJL-LTHGFNDWSA-N 0.000 description 2
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 2
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- HUCDRECCONJQHA-UHFFFAOYSA-N 1-[3-(tert-butylsulfamoyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-3-(pyridin-2-ylmethyl)urea Chemical compound C(C)(C)(C)NS(=O)(=O)C=1C=C(C=CC=1B1OC(C(O1)(C)C)(C)C)NC(=O)NCC1=NC=CC=C1 HUCDRECCONJQHA-UHFFFAOYSA-N 0.000 description 2
- LHHJUWUPIWPGAR-UHFFFAOYSA-N 1-benzyl-3-[3-(tert-butylsulfamoyl)-4-[2-(4-hydroxypiperidin-1-yl)-1,3-thiazol-5-yl]phenyl]urea Chemical compound C(C1=CC=CC=C1)NC(=O)NC1=CC(=C(C=C1)C1=CN=C(S1)N1CCC(CC1)O)S(NC(C)(C)C)(=O)=O LHHJUWUPIWPGAR-UHFFFAOYSA-N 0.000 description 2
- LWWGTPJWGYWBSY-UHFFFAOYSA-N 1-benzyl-3-[4-(2-bromo-1,3-thiazol-5-yl)-3-(tert-butylsulfamoyl)phenyl]urea Chemical compound C(C1=CC=CC=C1)NC(=O)NC1=CC(=C(C=C1)C1=CN=C(S1)Br)S(NC(C)(C)C)(=O)=O LWWGTPJWGYWBSY-UHFFFAOYSA-N 0.000 description 2
- YZUCHNQXRGQMQB-UHFFFAOYSA-N 2-(2-bromo-1,3-thiazol-5-yl)-N-tert-butyl-5-nitrobenzenesulfonamide Chemical compound BrC=1SC(=CN=1)C1=C(C=C(C=C1)[N+](=O)[O-])S(=O)(=O)NC(C)(C)C YZUCHNQXRGQMQB-UHFFFAOYSA-N 0.000 description 2
- SBQITYFGDYPTTI-UHFFFAOYSA-N 2-(3,6-dihydro-2H-pyran-2-yl)-1,3-thiazole Chemical compound O1C(CC=CC1)C=1SC=CN=1 SBQITYFGDYPTTI-UHFFFAOYSA-N 0.000 description 2
- NJDQOHQIXKZDPU-UHFFFAOYSA-N 2-(5-azidooxan-2-yl)-1,3-thiazole Chemical compound N(=[N+]=[N-])C1CCC(OC1)C=1SC=CN=1 NJDQOHQIXKZDPU-UHFFFAOYSA-N 0.000 description 2
- LDTHXGVTMLBBER-UHFFFAOYSA-N 2-O-benzyl 1-O-tert-butyl 5-hydroxypiperidine-1,2-dicarboxylate Chemical compound C(C1=CC=CC=C1)OC(=O)C1N(CC(CC1)O)C(=O)OC(C)(C)C LDTHXGVTMLBBER-UHFFFAOYSA-N 0.000 description 2
- FYYYQOOJNNIWOI-UHFFFAOYSA-N 2-bromo-N-(1-hydroxy-2-methylpropan-2-yl)-5-nitrobenzenesulfonamide Chemical compound BrC1=C(C=C(C=C1)[N+](=O)[O-])S(=O)(=O)NC(CO)(C)C FYYYQOOJNNIWOI-UHFFFAOYSA-N 0.000 description 2
- GSLTVFIVJMCNBH-UHFFFAOYSA-N 2-isocyanatopropane Chemical compound CC(C)N=C=O GSLTVFIVJMCNBH-UHFFFAOYSA-N 0.000 description 2
- JBUCHOBUXIMVDO-UHFFFAOYSA-N 3-methoxy-5-nitropyridine-2-carbonitrile Chemical compound COC1=CC([N+]([O-])=O)=CN=C1C#N JBUCHOBUXIMVDO-UHFFFAOYSA-N 0.000 description 2
- JQOIGFNJFBTVKO-UHFFFAOYSA-N 4-(propan-2-yloxycarbonylamino)bicyclo[2.2.2]octane-1-carboxylic acid Chemical compound C(C)(C)OC(=O)NC12CCC(CC1)(CC2)C(=O)O JQOIGFNJFBTVKO-UHFFFAOYSA-N 0.000 description 2
- RQJDUEKERVZLLU-UHFFFAOYSA-N 4-Hydroxybenzylamine Chemical compound NCC1=CC=C(O)C=C1 RQJDUEKERVZLLU-UHFFFAOYSA-N 0.000 description 2
- UCUHQXIAXJMZRI-UHFFFAOYSA-N 4-hydroxycyclohexane-1-carboxamide Chemical compound NC(=O)C1CCC(O)CC1 UCUHQXIAXJMZRI-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 2
- PNNKHGWTWQUUPU-UHFFFAOYSA-N 5-amino-2-bromo-n-(1-hydroxy-2-methylpropan-2-yl)benzenesulfonamide Chemical compound OCC(C)(C)NS(=O)(=O)C1=CC(N)=CC=C1Br PNNKHGWTWQUUPU-UHFFFAOYSA-N 0.000 description 2
- UXPLZIGNUAKISI-UHFFFAOYSA-N 6-(1,3-thiazol-2-yl)oxan-3-ol Chemical compound S1C(=NC=C1)C1CCC(CO1)O UXPLZIGNUAKISI-UHFFFAOYSA-N 0.000 description 2
- 108010079649 APOBEC-1 Deaminase Proteins 0.000 description 2
- 241001251200 Agelas Species 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
- 208000012526 B-cell neoplasm Diseases 0.000 description 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- OFLMDAQQBMNTJC-MGCOHNPYSA-N BrC1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(OC(C)(C)C)=O Chemical compound BrC1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(OC(C)(C)C)=O OFLMDAQQBMNTJC-MGCOHNPYSA-N 0.000 description 2
- SUCSSJQVZTUPFH-MGCOHNPYSA-N BrC1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(OC(C)C)=O Chemical compound BrC1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(OC(C)C)=O SUCSSJQVZTUPFH-MGCOHNPYSA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- SOCFYKYZRFJOQZ-MXVIHJGJSA-N C(C)(C)(C)NS(=O)(=O)C=1C=C(C=CC=1C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(=O)OC1CCCC1)NC(OC(C)C)=O Chemical compound C(C)(C)(C)NS(=O)(=O)C=1C=C(C=CC=1C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(=O)OC1CCCC1)NC(OC(C)C)=O SOCFYKYZRFJOQZ-MXVIHJGJSA-N 0.000 description 2
- YYARTLNXUSCLEE-KESTWPANSA-N C(C)(C)(C)NS(=O)(=O)C=1C=C(C=CC=1C1=CN=C(S1)[C@@H]1CC[C@H](CC1)OC(NC(C)C)=O)NC(OC(C)C)=O Chemical compound C(C)(C)(C)NS(=O)(=O)C=1C=C(C=CC=1C1=CN=C(S1)[C@@H]1CC[C@H](CC1)OC(NC(C)C)=O)NC(OC(C)C)=O YYARTLNXUSCLEE-KESTWPANSA-N 0.000 description 2
- OVXFEICGTUUFPE-WGSAOQKQSA-N C(C)(C)OC(NC1=CC(=C(C=C1)C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(=O)OC(C)C)S(NC(C)(C)C)(=O)=O)=O Chemical compound C(C)(C)OC(NC1=CC(=C(C=C1)C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(=O)OC(C)C)S(NC(C)(C)C)(=O)=O)=O OVXFEICGTUUFPE-WGSAOQKQSA-N 0.000 description 2
- HLOAZKNHRKVCQT-YHBQERECSA-N C(C1=CC=CC=C1)NC(=O)NC1=CC(=C(C=C1)C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(OC(C)(C)C)=O)S(NC(C)(C)C)(=O)=O Chemical compound C(C1=CC=CC=C1)NC(=O)NC1=CC(=C(C=C1)C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(OC(C)(C)C)=O)S(NC(C)(C)C)(=O)=O HLOAZKNHRKVCQT-YHBQERECSA-N 0.000 description 2
- LWGKIZXUYDQPJG-YHBQERECSA-N C(C1=CC=CC=C1)NC(=O)NC1=CC(=C(C=C1)C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(OC(C)C)=O)S(NC(C)(C)C)(=O)=O Chemical compound C(C1=CC=CC=C1)NC(=O)NC1=CC(=C(C=C1)C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(OC(C)C)=O)S(NC(C)(C)C)(=O)=O LWGKIZXUYDQPJG-YHBQERECSA-N 0.000 description 2
- XXYWYOAWAOXWKW-KYZUINATSA-N C(N)(=S)[C@@H]1CC[C@H](CC1)NC(OC(C)(C)C)=O Chemical compound C(N)(=S)[C@@H]1CC[C@H](CC1)NC(OC(C)(C)C)=O XXYWYOAWAOXWKW-KYZUINATSA-N 0.000 description 2
- VLOXPVONTDOATO-UHFFFAOYSA-N CC(C)(C)NS(C(C=C(C=C1)NC(O)=O)=C1C1=CN=C(C(CC2)CCC2NC(OC2COC2)=O)S1)(=O)=O Chemical compound CC(C)(C)NS(C(C=C(C=C1)NC(O)=O)=C1C1=CN=C(C(CC2)CCC2NC(OC2COC2)=O)S1)(=O)=O VLOXPVONTDOATO-UHFFFAOYSA-N 0.000 description 2
- HILAGAFOXBPCFN-KYZUINATSA-N CC(C)(C)OC(=O)N[C@H]1CC[C@H](C(N)=O)CC1 Chemical compound CC(C)(C)OC(=O)N[C@H]1CC[C@H](C(N)=O)CC1 HILAGAFOXBPCFN-KYZUINATSA-N 0.000 description 2
- 102000004091 Caspase-8 Human genes 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 108010031325 Cytidine deaminase Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000738911 Homo sapiens Mismatch repair endonuclease PMS2 Proteins 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 2
- MAXOESZLDBUFPF-UHFFFAOYSA-N N-tert-butyl-5-nitro-2-(1,3-thiazol-5-yl)benzenesulfonamide Chemical compound C(C)(C)(C)NS(=O)(=O)C1=C(C=CC(=C1)[N+](=O)[O-])C1=CN=CS1 MAXOESZLDBUFPF-UHFFFAOYSA-N 0.000 description 2
- MKYXZSHUJFVTDL-JCNLHEQBSA-N NC1=CC(=C(C=C1)C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(OC(C)C)=O)S(NC(C)(C)C)(=O)=O Chemical compound NC1=CC(=C(C=C1)C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(OC(C)C)=O)S(NC(C)(C)C)(=O)=O MKYXZSHUJFVTDL-JCNLHEQBSA-N 0.000 description 2
- 229910017906 NH3H2O Inorganic materials 0.000 description 2
- BPGISBWTZHSQSR-UHFFFAOYSA-N OS(CC(CC1)COC1C1=NC=CS1)(=O)=O Chemical compound OS(CC(CC1)COC1C1=NC=CS1)(=O)=O BPGISBWTZHSQSR-UHFFFAOYSA-N 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- AAKRLNVYLOZRGA-XYPYZODXSA-N S1C(=NC=C1)[C@@H]1CC[C@H](CC1)NC(OC(C)(C)C)=O Chemical compound S1C(=NC=C1)[C@@H]1CC[C@H](CC1)NC(OC(C)(C)C)=O AAKRLNVYLOZRGA-XYPYZODXSA-N 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000010115 WHIM syndrome Diseases 0.000 description 2
- 208000033355 WHIM syndrome 1 Diseases 0.000 description 2
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 2
- UCQLMACJHKAJAQ-UHFFFAOYSA-N [4-[5-[2-(tert-butylsulfamoyl)-4-(propan-2-yloxycarbonylamino)phenyl]-1,3-thiazol-2-yl]cyclohexyl]carbamic acid Chemical compound CC(C)OC(=O)Nc1ccc(-c2cnc(s2)C2CCC(CC2)NC(O)=O)c(c1)S(=O)(=O)NC(C)(C)C UCQLMACJHKAJAQ-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 229940126540 compound 41 Drugs 0.000 description 2
- 229940125844 compound 46 Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000012165 high-throughput sequencing Methods 0.000 description 2
- 102000050929 human PMS2 Human genes 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 210000001853 liver microsome Anatomy 0.000 description 2
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 125000006626 methoxycarbonylamino group Chemical group 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- LYMGWQBDAZOXDB-UHFFFAOYSA-N propan-2-yl 4-[5-[2-(tert-butylsulfamoyl)-4-(phenylmethoxycarbonylamino)phenyl]-1,3-thiazol-2-yl]piperazine-1-carboxylate Chemical compound C(C1=CC=CC=C1)OC(=O)NC1=CC(=C(C=C1)C1=CN=C(S1)N1CCN(CC1)C(=O)OC(C)C)S(NC(C)(C)C)(=O)=O LYMGWQBDAZOXDB-UHFFFAOYSA-N 0.000 description 2
- CGRGLIQCZBDTIQ-UHFFFAOYSA-N propan-2-yl 4-[5-[2-(tert-butylsulfamoyl)-4-(propan-2-yloxycarbonylamino)phenyl]-1,3-thiazol-2-yl]piperazine-1-carboxylate Chemical compound C(C)(C)(C)NS(=O)(=O)C1=C(C=CC(=C1)NC(=O)OC(C)C)C1=CN=C(S1)N1CCN(CC1)C(=O)OC(C)C CGRGLIQCZBDTIQ-UHFFFAOYSA-N 0.000 description 2
- XMLSOHWBJWVDQG-UHFFFAOYSA-N propan-2-yl N-(4-carbamothioyl-1-bicyclo[2.2.2]octanyl)carbamate Chemical compound C(N)(=S)C12CCC(CC1)(CC2)NC(OC(C)C)=O XMLSOHWBJWVDQG-UHFFFAOYSA-N 0.000 description 2
- LKTSTTMOMXHJEZ-UHFFFAOYSA-N propan-2-yl N-(4-carbamoyl-1-bicyclo[2.2.2]octanyl)carbamate Chemical compound C(N)(=O)C12CCC(CC1)(CC2)NC(OC(C)C)=O LKTSTTMOMXHJEZ-UHFFFAOYSA-N 0.000 description 2
- QLONUKGHMBQWPY-UHFFFAOYSA-N propan-2-yl N-(6-cyano-5-methoxypyridin-3-yl)carbamate Chemical compound C(#N)C1=C(C=C(C=N1)NC(OC(C)C)=O)OC QLONUKGHMBQWPY-UHFFFAOYSA-N 0.000 description 2
- RQAHNKQYNNOANH-UHFFFAOYSA-N propan-2-yl N-[1-[5-[2-(tert-butylsulfamoyl)-4-(propan-2-yloxycarbonylamino)phenyl]-1,3-thiazol-2-yl]piperidin-4-yl]carbamate Chemical compound C(C)(C)(C)NS(=O)(=O)C1=C(C=CC(=C1)NC(=O)OC(C)C)C1=CN=C(S1)N1CCC(CC1)NC(OC(C)C)=O RQAHNKQYNNOANH-UHFFFAOYSA-N 0.000 description 2
- MVHZJCYIBAMLCP-UHFFFAOYSA-N propan-2-yl N-[3-(tert-butylsulfamoyl)-4-[2-[3-(propan-2-yloxycarbonylamino)azetidin-1-yl]-1,3-thiazol-5-yl]phenyl]carbamate Chemical compound C(C)(C)(C)NS(=O)(=O)C=1C=C(C=CC=1C1=CN=C(S1)N1CC(C1)NC(=O)OC(C)C)NC(OC(C)C)=O MVHZJCYIBAMLCP-UHFFFAOYSA-N 0.000 description 2
- DGNXVPQINNAGJT-UHFFFAOYSA-N propan-2-yl N-[3-(tert-butylsulfamoyl)-4-[2-[3-(propan-2-yloxycarbonylamino)cyclobutyl]-1,3-thiazol-5-yl]phenyl]carbamate Chemical compound C(C)(C)(C)NS(=O)(=O)C=1C=C(C=CC=1C1=CN=C(S1)C1CC(C1)NC(=O)OC(C)C)NC(OC(C)C)=O DGNXVPQINNAGJT-UHFFFAOYSA-N 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000003007 single stranded DNA break Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- KCEWPVLEWGVSPM-WDEREUQCSA-N tert-butyl (2R,5S)-2-carbamothioyl-5-(propan-2-yloxycarbonylamino)piperidine-1-carboxylate Chemical compound CC(C)OC(=O)N[C@H]1CC[C@@H](N(C1)C(=O)OC(C)(C)C)C(=S)N KCEWPVLEWGVSPM-WDEREUQCSA-N 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AILYJCHMDSZEOL-VGMFFHCQSA-N (1S)-1-phenylethanol Chemical compound C1(=CC=CC=C1)[C@H](C)O.C1(=CC=CC=C1)[C@H](C)O AILYJCHMDSZEOL-VGMFFHCQSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- AAFJXZWCNVJTMK-GUCUJZIJSA-N (1s,2r)-1-[(2s)-oxiran-2-yl]-2-[(2r)-oxiran-2-yl]ethane-1,2-diol Chemical compound C([C@@H]1[C@H](O)[C@H](O)[C@H]2OC2)O1 AAFJXZWCNVJTMK-GUCUJZIJSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- QEHXDOJPVIHUDO-UHFFFAOYSA-N (2-fluorophenyl)methanol Chemical compound OCC1=CC=CC=C1F QEHXDOJPVIHUDO-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- DFTVUOBPXLNFJF-UHFFFAOYSA-N (4-carbamothioyl-1-bicyclo[2.2.2]octanyl) N-propan-2-ylcarbamate Chemical compound C(C)(C)NC(OC12CCC(CC1)(CC2)C(N)=S)=O DFTVUOBPXLNFJF-UHFFFAOYSA-N 0.000 description 1
- ZEPBRCCLUJOLFB-UHFFFAOYSA-N (4-carbamoyl-1-bicyclo[2.2.2]octanyl) N-propan-2-ylcarbamate Chemical compound C(C)(C)NC(OC12CCC(CC1)(CC2)C(N)=O)=O ZEPBRCCLUJOLFB-UHFFFAOYSA-N 0.000 description 1
- MPCKEDKQYPRBQI-UHFFFAOYSA-N (4-nitrophenyl) N-[4-bromo-3-(tert-butylsulfamoyl)phenyl]carbamate Chemical compound [N+](=O)([O-])C1=CC=C(C=C1)OC(NC1=CC(=C(C=C1)Br)S(NC(C)(C)C)(=O)=O)=O MPCKEDKQYPRBQI-UHFFFAOYSA-N 0.000 description 1
- OIIOPWHTJZYKIL-PMACEKPBSA-N (5S)-5-[[[5-[2-chloro-3-[2-chloro-3-[6-methoxy-5-[[[(2S)-5-oxopyrrolidin-2-yl]methylamino]methyl]pyrazin-2-yl]phenyl]phenyl]-3-methoxypyrazin-2-yl]methylamino]methyl]pyrrolidin-2-one Chemical compound C1(=C(N=C(C2=C(C(C3=CC=CC(=C3Cl)C3=NC(OC)=C(N=C3)CNC[C@H]3NC(=O)CC3)=CC=C2)Cl)C=N1)OC)CNC[C@H]1NC(=O)CC1 OIIOPWHTJZYKIL-PMACEKPBSA-N 0.000 description 1
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- ZCZVGQCBSJLDDS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine Chemical compound C1=CC=C2CCCNC2=N1 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- OXGVEGCNBSOKCY-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]-5-(propan-2-yloxycarbonylamino)piperidine-2-carboxylic acid Chemical compound C(C)(C)(C)OC(=O)N1C(CCC(C1)NC(=O)OC(C)C)C(=O)O OXGVEGCNBSOKCY-UHFFFAOYSA-N 0.000 description 1
- RMPQAVQRJOJFKF-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]-5-propan-2-yloxycarbonyloxypiperidine-2-carboxylic acid Chemical compound C(C)(C)(C)OC(=O)N1C(CCC(C1)OC(=O)OC(C)C)C(=O)O RMPQAVQRJOJFKF-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- YOQILGBVPQSEGU-UHFFFAOYSA-N 1-[4-[2-(4-aminocyclohexyl)-1,3-thiazol-5-yl]-3-(tert-butylsulfamoyl)phenyl]-3-benzylurea Chemical compound NC1CCC(CC1)C=1SC(=CN=1)C1=C(C=C(C=C1)NC(=O)NCC1=CC=CC=C1)S(NC(C)(C)C)(=O)=O YOQILGBVPQSEGU-UHFFFAOYSA-N 0.000 description 1
- OUJRFASNRSHFLG-UHFFFAOYSA-N 1-[4-[2-(4-aminopiperidin-1-yl)-1,3-thiazol-5-yl]-3-(tert-butylsulfamoyl)phenyl]-3-benzylurea Chemical compound NC1CCN(CC1)C=1SC(=CN=1)C1=C(C=C(C=C1)NC(=O)NCC1=CC=CC=C1)S(NC(C)(C)C)(=O)=O OUJRFASNRSHFLG-UHFFFAOYSA-N 0.000 description 1
- DHCDEHAEADDPQH-UHFFFAOYSA-N 1-[4-bromo-3-(tert-butylsulfamoyl)phenyl]-3-(pyridin-2-ylmethyl)urea Chemical compound BrC1=C(C=C(C=C1)NC(=O)NCC1=NC=CC=C1)S(NC(C)(C)C)(=O)=O DHCDEHAEADDPQH-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- NNZVKALEGZPYKL-UHFFFAOYSA-N 1-isocyanato-2-methylpropane Chemical compound CC(C)CN=C=O NNZVKALEGZPYKL-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- DUHBLGCXLOJNDU-UHFFFAOYSA-M 13-dodecyl-13-methyl-1,4,7,10-tetraoxa-13-azoniacyclopentadecane;bromide Chemical compound [Br-].CCCCCCCCCCCC[N+]1(C)CCOCCOCCOCCOCC1 DUHBLGCXLOJNDU-UHFFFAOYSA-M 0.000 description 1
- PNJUXCNBOXMPEY-UHFFFAOYSA-N 2,4-dihydropyrrolo[2,3-d]triazole Chemical compound N1N=NC2=C1C=CN2 PNJUXCNBOXMPEY-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
- QTMAZYGAVHCKKX-UHFFFAOYSA-N 2-[(4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl)methoxy]propane-1,3-diol Chemical compound NC1=NC=NC2=C1C(Br)=CN2COC(CO)CO QTMAZYGAVHCKKX-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- LILXDMFJXYAKMK-UHFFFAOYSA-N 2-bromo-1,1-diethoxyethane Chemical compound CCOC(CBr)OCC LILXDMFJXYAKMK-UHFFFAOYSA-N 0.000 description 1
- PHBZYADRQOPLIB-UHFFFAOYSA-N 2-bromo-N-tert-butyl-5-nitrobenzenesulfonamide Chemical compound BrC1=C(C=C(C=C1)[N+](=O)[O-])S(=O)(=O)NC(C)(C)C PHBZYADRQOPLIB-UHFFFAOYSA-N 0.000 description 1
- VFPWGZNNRSQPBT-UHFFFAOYSA-N 2-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1Br VFPWGZNNRSQPBT-UHFFFAOYSA-N 0.000 description 1
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- BZJNZXCHTMUOKG-UHFFFAOYSA-N 3,6-dihydro-2H-pyran-2-carbothioamide Chemical compound O1C(CC=CC1)C(N)=S BZJNZXCHTMUOKG-UHFFFAOYSA-N 0.000 description 1
- HSBWROPSDPNMTM-UHFFFAOYSA-N 3,6-dihydro-2h-pyran-2-carboxamide Chemical compound NC(=O)C1CC=CCO1 HSBWROPSDPNMTM-UHFFFAOYSA-N 0.000 description 1
- OWRKSSDYRPRYGL-UHFFFAOYSA-N 3,6-dihydro-2h-pyran-2-carboxylic acid Chemical compound OC(=O)C1CC=CCO1 OWRKSSDYRPRYGL-UHFFFAOYSA-N 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- KLCYDBAYYYVNFM-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]cyclobutane-1-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1CC(C(O)=O)C1 KLCYDBAYYYVNFM-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- YDPLFBIGFQFIDB-UHFFFAOYSA-N 3-chloropyridine-2-carbonitrile Chemical compound ClC1=CC=CN=C1C#N YDPLFBIGFQFIDB-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- BEETZOYEGNNBAS-UHFFFAOYSA-N 3-methoxypyridine-2-carbonitrile Chemical compound COC1=CC=CN=C1C#N BEETZOYEGNNBAS-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- IKHFDKLVBCRBHG-UHFFFAOYSA-N 4-(propan-2-ylcarbamoyloxy)bicyclo[2.2.2]octane-1-carboxylic acid Chemical compound C(C)(C)NC(=O)OC12CCC(CC1)(CC2)C(=O)O IKHFDKLVBCRBHG-UHFFFAOYSA-N 0.000 description 1
- KXMRDHPZQHAXML-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxycarbonylamino]cyclohexane-1-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1CCC(C(O)=O)CC1 KXMRDHPZQHAXML-UHFFFAOYSA-N 0.000 description 1
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 1
- IZDQVUOBMKKPRO-UHFFFAOYSA-N 5-amino-2-(2-bromo-1,3-thiazol-5-yl)-N-tert-butylbenzenesulfonamide Chemical compound NC=1C=CC(=C(C=1)S(=O)(=O)NC(C)(C)C)C1=CN=C(S1)Br IZDQVUOBMKKPRO-UHFFFAOYSA-N 0.000 description 1
- MHSHJIDNQVCZFL-UHFFFAOYSA-N 5-amino-2-[2-(3-aminoazetidin-1-yl)-1,3-thiazol-5-yl]-N-tert-butylbenzenesulfonamide Chemical compound NC=1C=CC(=C(C=1)S(=O)(=O)NC(C)(C)C)C1=CN=C(S1)N1CC(C1)N MHSHJIDNQVCZFL-UHFFFAOYSA-N 0.000 description 1
- GNNQMMWVGAJOCT-UHFFFAOYSA-N 5-amino-3-methoxypyridine-2-carbonitrile Chemical compound COC1=CC(N)=CN=C1C#N GNNQMMWVGAJOCT-UHFFFAOYSA-N 0.000 description 1
- ZYVPYBMJNRMYNT-UHFFFAOYSA-N 5-amino-N-tert-butyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide Chemical compound CC(C)(C)NS(=O)(=O)C1=C(C=CC(N)=C1)B1OC(C)(C)C(C)(C)O1 ZYVPYBMJNRMYNT-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- INHKXOPVZKYEHJ-UHFFFAOYSA-N 5-azidopiperidine-1,2-dicarboxylic acid Chemical compound OC(=O)C1CCC(N=[N+]=[N-])CN1C(O)=O INHKXOPVZKYEHJ-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- DKOIPAZERNXIHU-UHFFFAOYSA-N 5-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CC(O)CCC1C(O)=O DKOIPAZERNXIHU-UHFFFAOYSA-N 0.000 description 1
- CGRRUFNHHQCLDZ-UHFFFAOYSA-N 5-hydroxypyridine-2-carboxylic acid Natural products OC(=O)C1=CC=C(O)C=N1 CGRRUFNHHQCLDZ-UHFFFAOYSA-N 0.000 description 1
- JUOZQELUGOWECK-UHFFFAOYSA-N 5-methylsulfonyloxypiperidine-1,2-dicarboxylic acid Chemical compound CS(=O)(=O)OC1CCC(C(O)=O)N(C(O)=O)C1 JUOZQELUGOWECK-UHFFFAOYSA-N 0.000 description 1
- IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- FALMDFKWGXBTNQ-UHFFFAOYSA-N 6-(1,3-thiazol-2-yl)oxan-3-amine Chemical compound S1C(=NC=C1)C1CCC(CO1)N FALMDFKWGXBTNQ-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 101150079657 AICDA gene Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000012758 APOBEC-1 Deaminase Human genes 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 108090000963 Actin-related protein 2 Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- 208000004804 Adenomatous Polyps Diseases 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 206010053622 Asplenia Diseases 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 description 1
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 239000005711 Benzoic acid Chemical class 0.000 description 1
- 208000004860 Blast Crisis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- TUISDHGRXVEKIM-LJGSYFOKSA-N BrC1=CN=C(S1)[C@@H]1CC[C@H](CC1)O Chemical compound BrC1=CN=C(S1)[C@@H]1CC[C@H](CC1)O TUISDHGRXVEKIM-LJGSYFOKSA-N 0.000 description 1
- DTYKAKQJMQUIEV-MXVIHJGJSA-N BrC1=CN=C(S1)[C@@H]1CC[C@H](CC1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C Chemical compound BrC1=CN=C(S1)[C@@H]1CC[C@H](CC1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C DTYKAKQJMQUIEV-MXVIHJGJSA-N 0.000 description 1
- BYMUXCRTAQTSHR-ZKCHVHJHSA-N BrC1=CN=C(S1)[C@@H]1C[C@H](C1)NC(OC(C)(C)C)=O Chemical compound BrC1=CN=C(S1)[C@@H]1C[C@H](C1)NC(OC(C)(C)C)=O BYMUXCRTAQTSHR-ZKCHVHJHSA-N 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- VEJOABSDROCERQ-AZUAARDMSA-N C(C)(C)(C)NS(=O)(=O)C1=C(C=CC(=C1)NC(=O)OC(C)C)C1=CN=C(S1)[C@H]1CC[C@@H](CO1)NC(OC(C)C)=O Chemical compound C(C)(C)(C)NS(=O)(=O)C1=C(C=CC(=C1)NC(=O)OC(C)C)C1=CN=C(S1)[C@H]1CC[C@@H](CO1)NC(OC(C)C)=O VEJOABSDROCERQ-AZUAARDMSA-N 0.000 description 1
- CMDRFDAMEQXDBM-AQYVVDRMSA-N C(C)(C)(C)NS(=O)(=O)C1=C(C=CC(=C1)NC(=O)OCC1=C(C=CC=C1)F)C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(OC(C)C)=O Chemical compound C(C)(C)(C)NS(=O)(=O)C1=C(C=CC(=C1)NC(=O)OCC1=C(C=CC=C1)F)C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(OC(C)C)=O CMDRFDAMEQXDBM-AQYVVDRMSA-N 0.000 description 1
- FSEPNPYPSFWOKN-HZCBDIJESA-N C(C)(C)(C)NS(=O)(=O)C1=C(C=CC(=C1)NC(NCC1=CC=C(C=C1)O)=O)C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(OC(C)C)=O Chemical compound C(C)(C)(C)NS(=O)(=O)C1=C(C=CC(=C1)NC(NCC1=CC=C(C=C1)O)=O)C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(OC(C)C)=O FSEPNPYPSFWOKN-HZCBDIJESA-N 0.000 description 1
- YTKCMKPPYDAMRM-HZCBDIJESA-N C(C)(C)(C)NS(=O)(=O)C1=C(C=CC(=C1)NC(NCC1=CC=NC=C1)=O)C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(OC(C)C)=O Chemical compound C(C)(C)(C)NS(=O)(=O)C1=C(C=CC(=C1)NC(NCC1=CC=NC=C1)=O)C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(OC(C)C)=O YTKCMKPPYDAMRM-HZCBDIJESA-N 0.000 description 1
- MJSCDWAWTAIBKL-HZCBDIJESA-N C(C)(C)(C)NS(=O)(=O)C=1C=C(C=CC=1C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(=O)OC(C)C)NC(OCC1CCNCC1)=O Chemical compound C(C)(C)(C)NS(=O)(=O)C=1C=C(C=CC=1C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(=O)OC(C)C)NC(OCC1CCNCC1)=O MJSCDWAWTAIBKL-HZCBDIJESA-N 0.000 description 1
- ULMKNHYMJWIJBM-MEMLXQNLSA-N C(C)(C)(C)[Si](O[C@@H]1CC[C@H](CC1)C=1SC=CN=1)(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound C(C)(C)(C)[Si](O[C@@H]1CC[C@H](CC1)C=1SC=CN=1)(C1=CC=CC=C1)C1=CC=CC=C1 ULMKNHYMJWIJBM-MEMLXQNLSA-N 0.000 description 1
- IPIDQVHFAAEBAS-MGCOHNPYSA-N C(C)(C)NC(O[C@@H]1CC[C@H](CC1)C=1SC(=CN=1)Br)=O Chemical compound C(C)(C)NC(O[C@@H]1CC[C@H](CC1)C=1SC(=CN=1)Br)=O IPIDQVHFAAEBAS-MGCOHNPYSA-N 0.000 description 1
- TZFOLZSZDGPNLM-UHFFFAOYSA-N C(C)(C)OC(=O)NC1CCC(N(C1)C(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1 Chemical compound C(C)(C)OC(=O)NC1CCC(N(C1)C(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1 TZFOLZSZDGPNLM-UHFFFAOYSA-N 0.000 description 1
- MBQUTIYFCRDRKU-HZCBDIJESA-N C(C1=CC=CC=C1)NC(=O)NC1=CC(=C(C=C1)C1=C(N=C(S1)[C@@H]1CC[C@H](CC1)NC(OC(C)C)=O)F)S(NC(C)(C)C)(=O)=O Chemical compound C(C1=CC=CC=C1)NC(=O)NC1=CC(=C(C=C1)C1=C(N=C(S1)[C@@H]1CC[C@H](CC1)NC(OC(C)C)=O)F)S(NC(C)(C)C)(=O)=O MBQUTIYFCRDRKU-HZCBDIJESA-N 0.000 description 1
- AHTGMPRTHQAFMK-HZCBDIJESA-N C(C1=CC=CC=C1)NC(=O)NC1=CC(=C(C=C1)C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(OC1COC1)=O)S(NC(C)(C)C)(=O)=O Chemical compound C(C1=CC=CC=C1)NC(=O)NC1=CC(=C(C=C1)C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(OC1COC1)=O)S(NC(C)(C)C)(=O)=O AHTGMPRTHQAFMK-HZCBDIJESA-N 0.000 description 1
- OEMNWLSWHODVFU-LADGPHEKSA-N C(C1=CC=CC=C1)NC(=O)NC1=CC(=C(C=C1)C1=CN=C(S1)[C@H]1CC[C@@H](CO1)NC(OC(C)C)=O)S(NC(C)(C)C)(=O)=O Chemical compound C(C1=CC=CC=C1)NC(=O)NC1=CC(=C(C=C1)C1=CN=C(S1)[C@H]1CC[C@@H](CO1)NC(OC(C)C)=O)S(NC(C)(C)C)(=O)=O OEMNWLSWHODVFU-LADGPHEKSA-N 0.000 description 1
- JCFCDPYBABPJMM-LJGSYFOKSA-N C(N)(=S)[C@@H]1C[C@H](C1)NC(OC(C)(C)C)=O Chemical compound C(N)(=S)[C@@H]1C[C@H](C1)NC(OC(C)(C)C)=O JCFCDPYBABPJMM-LJGSYFOKSA-N 0.000 description 1
- 102100040397 C->U-editing enzyme APOBEC-1 Human genes 0.000 description 1
- BGGALFIXXQOTPY-NRFANRHFSA-N C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC Chemical compound C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC BGGALFIXXQOTPY-NRFANRHFSA-N 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- IYGJNPNWQKXUEY-UHFFFAOYSA-N C1C(C(=O)OCC2=CC=CC=C2)N(CC(C1)N)C(=O)OC(C)(C)C Chemical compound C1C(C(=O)OCC2=CC=CC=C2)N(CC(C1)N)C(=O)OC(C)(C)C IYGJNPNWQKXUEY-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- WMAAXQIQUXAERB-UHFFFAOYSA-N CC(C)(C)NS(=O)(=O)C1=C(C=CC(=C1)NC(=O)O)C2=CN=C(S2)Br Chemical compound CC(C)(C)NS(=O)(=O)C1=C(C=CC(=C1)NC(=O)O)C2=CN=C(S2)Br WMAAXQIQUXAERB-UHFFFAOYSA-N 0.000 description 1
- JPWHSYNHWPMKEB-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CC(CCC1C(=O)OCC1=CC=CC=C1)OS(C)(=O)=O Chemical compound CC(C)(C)OC(=O)N1CC(CCC1C(=O)OCC1=CC=CC=C1)OS(C)(=O)=O JPWHSYNHWPMKEB-UHFFFAOYSA-N 0.000 description 1
- LGULJOCYVVOMME-UHFFFAOYSA-N CC(C)OC(NC1=CN=C(C2=NC=C(C(C=CC(NC(O)=O)=C3)=C3S(NC(C)(C)C)(=O)=O)S2)C(OC)=C1)=O Chemical compound CC(C)OC(NC1=CN=C(C2=NC=C(C(C=CC(NC(O)=O)=C3)=C3S(NC(C)(C)C)(=O)=O)S2)C(OC)=C1)=O LGULJOCYVVOMME-UHFFFAOYSA-N 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- YWCGZTMLOAUAGP-UHFFFAOYSA-N COC=1C=C(C=NC=1C=1SC=CN=1)NC(OC(C)C)=O Chemical compound COC=1C=C(C=NC=1C=1SC=CN=1)NC(OC(C)C)=O YWCGZTMLOAUAGP-UHFFFAOYSA-N 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- 101100452003 Caenorhabditis elegans ape-1 gene Proteins 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 101100185881 Clostridium tetani (strain Massachusetts / E88) mutS2 gene Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102100026846 Cytidine deaminase Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 229940127399 DNA Polymerase Inhibitors Drugs 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 230000000970 DNA cross-linking effect Effects 0.000 description 1
- 231100000280 DNA damage induction Toxicity 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 102100027830 DNA repair protein XRCC2 Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 101100300807 Drosophila melanogaster spn-A gene Proteins 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010017708 Ganglioneuroblastoma Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- ZPLQIPFOCGIIHV-UHFFFAOYSA-N Gimeracil Chemical compound OC1=CC(=O)C(Cl)=CN1 ZPLQIPFOCGIIHV-UHFFFAOYSA-N 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 208000005234 Granulosa Cell Tumor Diseases 0.000 description 1
- 208000002125 Hemangioendothelioma Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000028523 Hereditary Complement Deficiency disease Diseases 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 208000002291 Histiocytic Sarcoma Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 description 1
- 101000649306 Homo sapiens DNA repair protein XRCC2 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000581326 Homo sapiens Mediator of DNA damage checkpoint protein 1 Proteins 0.000 description 1
- 101000755690 Homo sapiens Single-stranded DNA cytosine deaminase Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 201000004462 Leydig Cell Tumor Diseases 0.000 description 1
- 101150110531 MLH1 gene Proteins 0.000 description 1
- 101150102506 MSH3 gene Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000035771 Malignant Sertoli-Leydig cell tumor of the ovary Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100027643 Mediator of DNA damage checkpoint protein 1 Human genes 0.000 description 1
- 201000009574 Mesenchymal Chondrosarcoma Diseases 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 101150033433 Msh2 gene Proteins 0.000 description 1
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 1
- 208000013811 Mueller mixed tumour Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100381525 Mus musculus Bcl6 gene Proteins 0.000 description 1
- NBUHNHAIHXXZOK-UHFFFAOYSA-N N(=[N+]=[N-])C1CCC(N(C1)C(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1 Chemical compound N(=[N+]=[N-])C1CCC(N(C1)C(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1 NBUHNHAIHXXZOK-UHFFFAOYSA-N 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 description 1
- NJFQKSJHHIOZJR-UHFFFAOYSA-N N-[3-(tert-butylsulfamoyl)-4-(2-piperazin-1-yl-1,3-thiazol-5-yl)phenyl]acetamide Chemical compound C(C)(C)(C)NS(=O)(=O)C=1C=C(C=CC=1C1=CN=C(S1)N1CCNCC1)NC(C)=O NJFQKSJHHIOZJR-UHFFFAOYSA-N 0.000 description 1
- RDCVZBXRVABOLI-UHFFFAOYSA-N N-[3-(tert-butylsulfamoyl)-4-[2-(4-hydroxypiperidin-1-yl)-1,3-thiazol-5-yl]phenyl]acetamide Chemical compound C(C)(C)(C)NS(=O)(=O)C=1C=C(C=CC=1C1=CN=C(S1)N1CCC(CC1)O)NC(C)=O RDCVZBXRVABOLI-UHFFFAOYSA-N 0.000 description 1
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Substances BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 1
- KAOILEJJORNFBS-KOMQPUFPSA-N NC1=CC(=C(C=C1)C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(OC1COC1)=O)S(NC(C)(C)C)(=O)=O Chemical compound NC1=CC(=C(C=C1)C1=CN=C(S1)[C@@H]1CC[C@H](CC1)NC(OC1COC1)=O)S(NC(C)(C)C)(=O)=O KAOILEJJORNFBS-KOMQPUFPSA-N 0.000 description 1
- MYMMCCKCPOJPTP-CTYIDZIISA-N NC1=CC(=C(C=C1)C1=CN=C(S1)[C@@H]1C[C@H](C1)NC(OC(C)(C)C)=O)S(NC(C)(C)C)(=O)=O Chemical compound NC1=CC(=C(C=C1)C1=CN=C(S1)[C@@H]1C[C@H](C1)NC(OC(C)(C)C)=O)S(NC(C)(C)C)(=O)=O MYMMCCKCPOJPTP-CTYIDZIISA-N 0.000 description 1
- MWMUNJCUEVGCMF-UMSPYCQHSA-N NC=1C=CC(=C(C=1)S(=O)(=O)NC(C)(C)C)C1=CN=C(S1)[C@@H]1C[C@H](C1)N Chemical compound NC=1C=CC(=C(C=1)S(=O)(=O)NC(C)(C)C)C1=CN=C(S1)[C@@H]1C[C@H](C1)N MWMUNJCUEVGCMF-UMSPYCQHSA-N 0.000 description 1
- YOQILGBVPQSEGU-MXVIHJGJSA-N N[C@@H]1CC[C@H](CC1)C=1SC(=CN=1)C1=C(C=C(C=C1)NC(=O)NCC1=CC=CC=C1)S(NC(C)(C)C)(=O)=O Chemical compound N[C@@H]1CC[C@H](CC1)C=1SC(=CN=1)C1=C(C=C(C=C1)NC(=O)NCC1=CC=CC=C1)S(NC(C)(C)C)(=O)=O YOQILGBVPQSEGU-MXVIHJGJSA-N 0.000 description 1
- PLYSGPIJOTWPII-WKILWMFISA-N N[C@@H]1CC[C@H](CC1)C=1SC(=CN=1)C1=C(C=C(C=C1)NC(OC(C)C)=O)S(NC(C)(C)C)(=O)=O Chemical compound N[C@@H]1CC[C@H](CC1)C=1SC(=CN=1)C1=C(C=C(C=C1)NC(OC(C)C)=O)S(NC(C)(C)C)(=O)=O PLYSGPIJOTWPII-WKILWMFISA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000007871 Odontogenic Tumors Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 244000146510 Pereskia bleo Species 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102000001218 Rec A Recombinases Human genes 0.000 description 1
- 108010055016 Rec A Recombinases Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- AAJMVDKYSVWTIZ-KYZUINATSA-N S1C(=NC=C1)[C@@H]1C[C@H](C1)NC(OC(C)(C)C)=O Chemical compound S1C(=NC=C1)[C@@H]1C[C@H](C1)NC(OC(C)(C)C)=O AAJMVDKYSVWTIZ-KYZUINATSA-N 0.000 description 1
- 101000825209 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Meiosis-specific protein SPO11 Proteins 0.000 description 1
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- IOSLINNLJFQMFF-XMMPIXPASA-N [(2R)-1-[[4-[[3-[(4-fluorophenyl)methylsulfanyl]phenoxy]methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound FC1=CC=C(CSC=2C=C(OCC3=CC=C(CN4[C@H](CCC4)CO)C=C3)C=CC=2)C=C1 IOSLINNLJFQMFF-XMMPIXPASA-N 0.000 description 1
- RQPLRXIGVXUEJB-LJAQVGFWSA-N [(2S)-1-methylpyrrolidin-2-yl] N-[4-[2-[4-(benzylcarbamoyloxy)piperidin-1-yl]-1,3-thiazol-5-yl]-3-(tert-butylsulfamoyl)phenyl]-N-methylcarbamate Chemical compound CN1[C@H](CCC1)OC(N(C1=CC(=C(C=C1)C1=CN=C(S1)N1CCC(CC1)OC(NCC1=CC=CC=C1)=O)S(NC(C)(C)C)(=O)=O)C)=O RQPLRXIGVXUEJB-LJAQVGFWSA-N 0.000 description 1
- VCOJPHPOVDIRJK-LURJTMIESA-N [(2s)-1-methylpyrrolidin-2-yl]methanol Chemical compound CN1CCC[C@H]1CO VCOJPHPOVDIRJK-LURJTMIESA-N 0.000 description 1
- AVARVUJNXCATDS-UHFFFAOYSA-N [1-[5-[2-(tert-butylsulfamoyl)-4-[(4-nitrophenoxy)carbonylamino]phenyl]-1,3-thiazol-2-yl]piperidin-4-yl] N-benzylcarbamate Chemical compound C(C1=CC=CC=C1)NC(OC1CCN(CC1)C=1SC(=CN=1)C1=C(C=C(C=C1)NC(=O)OC1=CC=C(C=C1)[N+](=O)[O-])S(NC(C)(C)C)(=O)=O)=O AVARVUJNXCATDS-UHFFFAOYSA-N 0.000 description 1
- AHJSZYNCYTWAQL-RUZDIDTESA-N [1-[5-[2-(tert-butylsulfamoyl)-4-[[(2R)-1-methylpyrrolidin-2-yl]methoxycarbonylamino]phenyl]-1,3-thiazol-2-yl]piperidin-4-yl] N-benzylcarbamate Chemical compound C(C1=CC=CC=C1)NC(OC1CCN(CC1)C=1SC(=CN=1)C1=C(C=C(C=C1)NC(=O)OC[C@@H]1N(CCC1)C)S(NC(C)(C)C)(=O)=O)=O AHJSZYNCYTWAQL-RUZDIDTESA-N 0.000 description 1
- RZBCLYNNBGMPFP-UHFFFAOYSA-N [1-[5-[4-(benzylcarbamoylamino)-2-(tert-butylsulfamoyl)phenyl]-1,3-thiazol-2-yl]piperidin-4-yl] N-propan-2-ylcarbamate Chemical compound C(C)(C)NC(OC1CCN(CC1)C=1SC(=CN=1)C1=C(C=C(C=C1)NC(NCC1=CC=CC=C1)=O)S(NC(C)(C)C)(=O)=O)=O RZBCLYNNBGMPFP-UHFFFAOYSA-N 0.000 description 1
- BSGIFVXPAUTKCM-UHFFFAOYSA-N [1-[5-[4-acetamido-2-(tert-butylsulfamoyl)phenyl]-1,3-thiazol-2-yl]piperidin-4-yl] N-benzylcarbamate Chemical compound C(C1=CC=CC=C1)NC(OC1CCN(CC1)C=1SC(=CN=1)C1=C(C=C(C=C1)NC(C)=O)S(NC(C)(C)C)(=O)=O)=O BSGIFVXPAUTKCM-UHFFFAOYSA-N 0.000 description 1
- GVUSOEMHLFPTSL-UHFFFAOYSA-N [1-[5-[4-amino-2-(tert-butylsulfamoyl)phenyl]-1,3-thiazol-2-yl]piperidin-4-yl] N-benzylcarbamate Chemical compound C(C1=CC=CC=C1)NC(OC1CCN(CC1)C=1SC(=CN=1)C1=C(C=C(C=C1)N)S(NC(C)(C)C)(=O)=O)=O GVUSOEMHLFPTSL-UHFFFAOYSA-N 0.000 description 1
- JBTWLTMBISFMJS-UHFFFAOYSA-N [3-(tert-butylsulfamoyl)-4-[2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]piperidin-1-yl]-1,3-thiazol-5-yl]phenyl]carbamic acid Chemical compound CC(C)(C)NS(=O)(=O)c1cc(NC(O)=O)ccc1-c1cnc(s1)N1CCC(CC1)NC(=O)OC(C)(C)C JBTWLTMBISFMJS-UHFFFAOYSA-N 0.000 description 1
- ZACGWYXHUDLXRS-UHFFFAOYSA-N [4-(1,3-thiazol-2-yl)-1-bicyclo[2.2.2]octanyl] N-propan-2-ylcarbamate Chemical compound C(C)(C)NC(OC12CCC(CC1)(CC2)C=1SC=CN=1)=O ZACGWYXHUDLXRS-UHFFFAOYSA-N 0.000 description 1
- HDZQOBQDNSPOFA-UHFFFAOYSA-N [4-(5-bromo-1,3-thiazol-2-yl)-1-bicyclo[2.2.2]octanyl] N-propan-2-ylcarbamate Chemical compound C(C)(C)NC(OC12CCC(CC1)(CC2)C=1SC(=CN=1)Br)=O HDZQOBQDNSPOFA-UHFFFAOYSA-N 0.000 description 1
- DKHVWZAPUAYXAY-UHFFFAOYSA-N [4-[5-[4-(benzylcarbamoylamino)-2-(tert-butylsulfamoyl)phenyl]-1,3-thiazol-2-yl]-1-bicyclo[2.2.2]octanyl] N-propan-2-ylcarbamate Chemical compound C(C)(C)NC(OC12CCC(CC1)(CC2)C=1SC(=CN=1)C1=C(C=C(C=C1)NC(NCC1=CC=CC=C1)=O)S(NC(C)(C)C)(=O)=O)=O DKHVWZAPUAYXAY-UHFFFAOYSA-N 0.000 description 1
- KNBOZLNIXZFLDB-WGSAOQKQSA-N [Si](C1=CC=CC=C1)(C1=CC=CC=C1)(C(C)(C)C)O[C@@H]1CC[C@H](CC1)C(=O)N Chemical compound [Si](C1=CC=CC=C1)(C1=CC=CC=C1)(C(C)(C)C)O[C@@H]1CC[C@H](CC1)C(=O)N KNBOZLNIXZFLDB-WGSAOQKQSA-N 0.000 description 1
- NRTJMUUERDMBPL-WGSAOQKQSA-N [Si](C1=CC=CC=C1)(C1=CC=CC=C1)(C(C)(C)C)O[C@@H]1CC[C@H](CC1)C(N)=S Chemical compound [Si](C1=CC=CC=C1)(C1=CC=CC=C1)(C(C)(C)C)O[C@@H]1CC[C@H](CC1)C(N)=S NRTJMUUERDMBPL-WGSAOQKQSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000006336 acinar cell carcinoma Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 208000010029 ameloblastoma Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108700028529 archaeal RadA Proteins 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 230000033590 base-excision repair Effects 0.000 description 1
- 201000007551 basophilic adenocarcinoma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- PUNFICOCZAPAJV-UHFFFAOYSA-N bicyclo[2.2.2]octane-4-carboxylic acid Chemical compound C1CC2CCC1(C(=O)O)CC2 PUNFICOCZAPAJV-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 201000011143 bone giant cell tumor Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical group 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 238000000633 chiral stationary phase gas chromatography Methods 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000003927 comet assay Methods 0.000 description 1
- 231100000170 comet assay Toxicity 0.000 description 1
- 201000002388 complement deficiency Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 210000001096 cystic duct Anatomy 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229950000758 dianhydrogalactitol Drugs 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- SACNIGZYDTUHKB-UHFFFAOYSA-N ditert-butyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C(C)(C)C)C(C)(C)C SACNIGZYDTUHKB-UHFFFAOYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical class CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- LVSGIRALGRTDAN-UHFFFAOYSA-N ethyl 3,6-dihydro-2h-pyran-2-carboxylate Chemical compound CCOC(=O)C1CC=CCO1 LVSGIRALGRTDAN-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- DBPFRRFGLYGEJI-UHFFFAOYSA-N ethyl glyoxylate Chemical compound CCOC(=O)C=O DBPFRRFGLYGEJI-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 201000008815 extraosseous osteosarcoma Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 125000004175 fluorobenzyl group Chemical group 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
- 229940020967 gemzar Drugs 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001102 germinal center b cell Anatomy 0.000 description 1
- 229950009822 gimeracil Drugs 0.000 description 1
- 101150117187 glmS gene Proteins 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 102000057079 human MSH2 Human genes 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 208000018949 hyper-IgM syndrome type 2 Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229940099279 idamycin Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 201000001373 immunodeficiency with hyper-IgM type 2 Diseases 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229950010897 iproplatin Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 239000000436 ligase inhibitor Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000000014 lung giant cell carcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000017156 mRNA modification Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 201000004102 malignant granular cell myoblastoma Diseases 0.000 description 1
- 201000006812 malignant histiocytosis Diseases 0.000 description 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 208000000516 mast-cell leukemia Diseases 0.000 description 1
- 201000008749 mast-cell sarcoma Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- BBIBFSXYIYYHNI-UHFFFAOYSA-N methyl 4-(propan-2-ylcarbamoyloxy)bicyclo[2.2.2]octane-1-carboxylate Chemical compound C(C)(C)NC(=O)OC12CCC(CC1)(CC2)C(=O)OC BBIBFSXYIYYHNI-UHFFFAOYSA-N 0.000 description 1
- RDTHVJQZDRCWOS-UHFFFAOYSA-N methyl 4-(propan-2-yloxycarbonylamino)bicyclo[2.2.2]octane-1-carboxylate Chemical compound C(C)(C)OC(=O)NC12CCC(CC1)(CC2)C(=O)OC RDTHVJQZDRCWOS-UHFFFAOYSA-N 0.000 description 1
- LUBWUSMZFMBOIQ-UHFFFAOYSA-N methyl 4-hydroxybicyclo[2.2.2]octane-1-carboxylate Chemical compound C1CC2(O)CCC1(C(=O)OC)CC2 LUBWUSMZFMBOIQ-UHFFFAOYSA-N 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000022499 mismatch repair cancer syndrome Diseases 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- QXYYYPFGTSJXNS-UHFFFAOYSA-N mitozolomide Chemical compound N1=NN(CCCl)C(=O)N2C1=C(C(=O)N)N=C2 QXYYYPFGTSJXNS-UHFFFAOYSA-N 0.000 description 1
- 229950005967 mitozolomide Drugs 0.000 description 1
- 201000010225 mixed cell type cancer Diseases 0.000 description 1
- 208000029638 mixed neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 238000007838 multiplex ligation-dependent probe amplification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 101150049514 mutL gene Proteins 0.000 description 1
- 101150013854 mutS gene Proteins 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- LPOIGVZLNWEGJG-UHFFFAOYSA-N n-benzyl-5-(4-methylpiperazin-1-yl)-2-nitroaniline Chemical compound C1CN(C)CCN1C1=CC=C([N+]([O-])=O)C(NCC=2C=CC=CC=2)=C1 LPOIGVZLNWEGJG-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 208000004613 nanophthalmos 3 Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000001020 neural plate Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- KPMKNHGAPDCYLP-UHFFFAOYSA-N nimustine hydrochloride Chemical compound Cl.CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 KPMKNHGAPDCYLP-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000004005 nitrosamines Chemical class 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000027825 odontogenic neoplasm Diseases 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 231100000822 oral exposure Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- 208000012221 ovarian Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- QMLWSAXEQSBAAQ-UHFFFAOYSA-N oxetan-3-ol Chemical compound OC1COC1 QMLWSAXEQSBAAQ-UHFFFAOYSA-N 0.000 description 1
- LFSMHRHEOPZZFU-UHFFFAOYSA-N oxetan-3-yl carbamate Chemical class NC(=O)OC1COC1 LFSMHRHEOPZZFU-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 201000010210 papillary cystadenocarcinoma Diseases 0.000 description 1
- 208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 1
- 201000001494 papillary transitional carcinoma Diseases 0.000 description 1
- 208000031101 papillary transitional cell carcinoma Diseases 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 206010035059 pineocytoma Diseases 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 206010035485 plasmacytosis Diseases 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- LOCAUIUYQHSGLN-UHFFFAOYSA-N propan-2-yl 4-[5-[2-(tert-butylsulfamoyl)-4-(pyridin-2-ylmethylcarbamoylamino)phenyl]-1,3-thiazol-2-yl]piperidine-1-carboxylate Chemical compound C(C)(C)(C)NS(=O)(=O)C1=C(C=CC(=C1)NC(NCC1=NC=CC=C1)=O)C1=CN=C(S1)C1CCN(CC1)C(=O)OC(C)C LOCAUIUYQHSGLN-UHFFFAOYSA-N 0.000 description 1
- ICAJPASOMHSTNX-UHFFFAOYSA-N propan-2-yl 4-[5-[4-acetamido-2-(tert-butylsulfamoyl)phenyl]-1,3-thiazol-2-yl]piperazine-1-carboxylate Chemical compound C(C)(=O)NC1=CC(=C(C=C1)C1=CN=C(S1)N1CCN(CC1)C(=O)OC(C)C)S(NC(C)(C)C)(=O)=O ICAJPASOMHSTNX-UHFFFAOYSA-N 0.000 description 1
- FEUUVOWZDUCLFB-UHFFFAOYSA-N propan-2-yl 4-[5-[4-amino-2-(tert-butylsulfamoyl)phenyl]-1,3-thiazol-2-yl]piperazine-1-carboxylate Chemical compound NC1=CC(=C(C=C1)C1=CN=C(S1)N1CCN(CC1)C(=O)OC(C)C)S(NC(C)(C)C)(=O)=O FEUUVOWZDUCLFB-UHFFFAOYSA-N 0.000 description 1
- DCFDTYGHQHJQIU-UHFFFAOYSA-N propan-2-yl N-(6-carbamothioyl-5-methoxypyridin-3-yl)carbamate Chemical compound C(N)(=S)C1=C(C=C(C=N1)NC(OC(C)C)=O)OC DCFDTYGHQHJQIU-UHFFFAOYSA-N 0.000 description 1
- UOOWYHBGDYYJJB-VHSXEESVSA-N propan-2-yl N-[(3S,6R)-6-(1,3-thiazol-2-yl)oxan-3-yl]carbamate Chemical compound S1C(=NC=C1)[C@H]1CC[C@@H](CO1)NC(OC(C)C)=O UOOWYHBGDYYJJB-VHSXEESVSA-N 0.000 description 1
- FUABTONWFOADIC-DTWKUNHWSA-N propan-2-yl N-[(3S,6R)-6-(5-bromo-1,3-thiazol-2-yl)oxan-3-yl]carbamate Chemical compound BrC1=CN=C(S1)[C@H]1CC[C@@H](CO1)NC(OC(C)C)=O FUABTONWFOADIC-DTWKUNHWSA-N 0.000 description 1
- DBZWEUWVEPUMGD-AZUAARDMSA-N propan-2-yl N-[(3S,6R)-6-[5-[2-(tert-butylsulfamoyl)-4-(propan-2-yloxycarbonylamino)phenyl]-1,3-thiazol-2-yl]piperidin-3-yl]carbamate Chemical compound C(C)(C)(C)NS(=O)(=O)C1=C(C=CC(=C1)NC(=O)OC(C)C)C1=CN=C(S1)[C@H]1CC[C@@H](CN1)NC(OC(C)C)=O DBZWEUWVEPUMGD-AZUAARDMSA-N 0.000 description 1
- BLXJQCFQXDUSQT-UHFFFAOYSA-N propan-2-yl N-[1-[5-[4-(benzylcarbamoylamino)-2-(tert-butylsulfamoyl)phenyl]-1,3-thiazol-2-yl]piperidin-4-yl]carbamate Chemical compound C(C1=CC=CC=C1)NC(=O)NC1=CC(=C(C=C1)C1=CN=C(S1)N1CCC(CC1)NC(OC(C)C)=O)S(NC(C)(C)C)(=O)=O BLXJQCFQXDUSQT-UHFFFAOYSA-N 0.000 description 1
- OVXFEICGTUUFPE-UHFFFAOYSA-N propan-2-yl N-[3-(tert-butylsulfamoyl)-4-[2-[4-(propan-2-yloxycarbonylamino)cyclohexyl]-1,3-thiazol-5-yl]phenyl]carbamate Chemical compound C(C)(C)(C)NS(=O)(=O)C=1C=C(C=CC=1C1=CN=C(S1)C1CCC(CC1)NC(=O)OC(C)C)NC(OC(C)C)=O OVXFEICGTUUFPE-UHFFFAOYSA-N 0.000 description 1
- DZGGDCTWEZQEHZ-UHFFFAOYSA-N propan-2-yl N-[3-(tert-butylsulfamoyl)-4-[2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]cyclohexyl]-1,3-thiazol-5-yl]phenyl]carbamate Chemical compound C(C)(C)(C)OC(=O)NC1CCC(CC1)C=1SC(=CN=1)C1=C(C=C(C=C1)NC(OC(C)C)=O)S(NC(C)(C)C)(=O)=O DZGGDCTWEZQEHZ-UHFFFAOYSA-N 0.000 description 1
- IHNIQDLDZZYGNY-UHFFFAOYSA-N propan-2-yl N-[3-(tert-butylsulfamoyl)-4-[2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]piperidin-1-yl]-1,3-thiazol-5-yl]phenyl]carbamate Chemical compound C(C)(C)(C)OC(=O)NC1CCN(CC1)C=1SC(=CN=1)C1=C(C=C(C=C1)NC(OC(C)C)=O)S(NC(C)(C)C)(=O)=O IHNIQDLDZZYGNY-UHFFFAOYSA-N 0.000 description 1
- KNIBJZGWXQOYCM-UHFFFAOYSA-N propan-2-yl N-[4-(1,3-thiazol-2-yl)-1-bicyclo[2.2.2]octanyl]carbamate Chemical compound S1C(=NC=C1)C12CCC(CC1)(CC2)NC(OC(C)C)=O KNIBJZGWXQOYCM-UHFFFAOYSA-N 0.000 description 1
- BPTCBKOEFFKPEP-UHFFFAOYSA-N propan-2-yl N-[4-(5-bromo-1,3-thiazol-2-yl)-1-bicyclo[2.2.2]octanyl]carbamate Chemical compound BrC1=CN=C(S1)C12CCC(CC1)(CC2)NC(OC(C)C)=O BPTCBKOEFFKPEP-UHFFFAOYSA-N 0.000 description 1
- HBEFYOYQWKSEHE-UHFFFAOYSA-N propan-2-yl N-[6-(5-bromo-1,3-thiazol-2-yl)-5-methoxypyridin-3-yl]carbamate Chemical compound COC1=C(N=CC(NC(=O)OC(C)C)=C1)C1=NC=C(Br)S1 HBEFYOYQWKSEHE-UHFFFAOYSA-N 0.000 description 1
- CURPPQXIGOORCS-UHFFFAOYSA-N propan-2-yl N-[6-[5-[4-acetamido-2-(tert-butylsulfamoyl)phenyl]-1,3-thiazol-2-yl]-5-methoxypyridin-3-yl]carbamate Chemical compound C(C)(=O)NC1=CC(=C(C=C1)C1=CN=C(S1)C1=C(C=C(C=N1)NC(OC(C)C)=O)OC)S(NC(C)(C)C)(=O)=O CURPPQXIGOORCS-UHFFFAOYSA-N 0.000 description 1
- RIIFRPQDYGBHNN-UHFFFAOYSA-N propan-2-yl N-[6-[5-[4-amino-2-(tert-butylsulfamoyl)phenyl]-1,3-thiazol-2-yl]-5-methoxypyridin-3-yl]carbamate Chemical compound NC1=CC(=C(C=C1)C1=CN=C(S1)C1=C(C=C(C=N1)NC(OC(C)C)=O)OC)S(NC(C)(C)C)(=O)=O RIIFRPQDYGBHNN-UHFFFAOYSA-N 0.000 description 1
- IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- SHNUBALDGXWUJI-UHFFFAOYSA-N pyridin-2-ylmethanol Chemical compound OCC1=CC=CC=N1 SHNUBALDGXWUJI-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 229930185107 quinolinone Natural products 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000013120 recombinational repair Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 208000014212 sarcomatoid carcinoma Diseases 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000001963 scanning near-field photolithography Methods 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- FVLVBPDQNARYJU-UHFFFAOYSA-N semustine Chemical compound CC1CCC(NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-UHFFFAOYSA-N 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000018381 sister chromatid cohesion Effects 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035892 strand transfer Effects 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- VRGWAGKJBPOQPF-NWDGAFQWSA-N tert-butyl (2R,5S)-2-(5-bromo-1,3-thiazol-2-yl)-5-(propan-2-yloxycarbonylamino)piperidine-1-carboxylate Chemical compound BrC1=CN=C(S1)[C@@H]1N(C[C@H](CC1)NC(=O)OC(C)C)C(=O)OC(C)(C)C VRGWAGKJBPOQPF-NWDGAFQWSA-N 0.000 description 1
- WLZRWMXLHNAASA-QWHCGFSZSA-N tert-butyl (2R,5S)-5-(propan-2-yloxycarbonylamino)-2-(1,3-thiazol-2-yl)piperidine-1-carboxylate Chemical compound C(C)(C)OC(=O)N[C@H]1CC[C@@H](N(C1)C(=O)OC(C)(C)C)C=1SC=CN=1 WLZRWMXLHNAASA-QWHCGFSZSA-N 0.000 description 1
- FMORTOPAHLNCBG-UHFFFAOYSA-N tert-butyl 2-carbamoyl-5-(propan-2-yloxycarbonylamino)piperidine-1-carboxylate Chemical compound C(N)(=O)C1N(CC(CC1)NC(=O)OC(C)C)C(=O)OC(C)(C)C FMORTOPAHLNCBG-UHFFFAOYSA-N 0.000 description 1
- JATDSZSSQBTFMP-UHFFFAOYSA-N tert-butyl N-[1-[5-[4-(benzylcarbamoylamino)-2-(tert-butylsulfamoyl)phenyl]-1,3-thiazol-2-yl]piperidin-4-yl]carbamate Chemical compound C(C1=CC=CC=C1)NC(=O)NC1=CC(=C(C=C1)C1=CN=C(S1)N1CCC(CC1)NC(OC(C)(C)C)=O)S(NC(C)(C)C)(=O)=O JATDSZSSQBTFMP-UHFFFAOYSA-N 0.000 description 1
- WFPDMIKFIHZTQX-UHFFFAOYSA-N tert-butyl N-[4-[5-[4-(benzylcarbamoylamino)-2-(tert-butylsulfamoyl)phenyl]-1,3-thiazol-2-yl]cyclohex-3-en-1-yl]carbamate Chemical compound C(C)(C)(C)OC(NC1CC=C(CC1)C=1SC(=CN=1)C1=C(C=C(C=C1)NC(NCC1=CC=CC=C1)=O)S(NC(C)(C)C)(=O)=O)=O WFPDMIKFIHZTQX-UHFFFAOYSA-N 0.000 description 1
- HLOAZKNHRKVCQT-UHFFFAOYSA-N tert-butyl N-[4-[5-[4-(benzylcarbamoylamino)-2-(tert-butylsulfamoyl)phenyl]-1,3-thiazol-2-yl]cyclohexyl]carbamate Chemical compound C(C1=CC=CC=C1)NC(=O)NC1=CC(=C(C=C1)C1=CN=C(S1)C1CCC(CC1)NC(OC(C)(C)C)=O)S(NC(C)(C)C)(=O)=O HLOAZKNHRKVCQT-UHFFFAOYSA-N 0.000 description 1
- NEMXVXVJGXZDRR-UHFFFAOYSA-N tert-butyl n-(azetidin-3-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CNC1 NEMXVXVJGXZDRR-UHFFFAOYSA-N 0.000 description 1
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 150000004905 tetrazines Chemical class 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000033587 transcription-coupled nucleotide-excision repair Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000007482 whole exome sequencing Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556763P | 2017-09-11 | 2017-09-11 | |
| US62/556,763 | 2017-09-11 | ||
| US201862711959P | 2018-07-30 | 2018-07-30 | |
| US62/711,959 | 2018-07-30 | ||
| PCT/US2018/050391 WO2019051465A1 (en) | 2017-09-11 | 2018-09-11 | RAD51 INHIBITORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533329A JP2020533329A (ja) | 2020-11-19 |
| JP2020533329A5 JP2020533329A5 (es) | 2021-09-24 |
| JP7265537B2 true JP7265537B2 (ja) | 2023-04-26 |
Family
ID=63722779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020514206A Active JP7265537B2 (ja) | 2017-09-11 | 2018-09-11 | Ｒａｄ５１阻害剤 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US10590122B2 (es) |
| EP (2) | EP3681884B1 (es) |
| JP (1) | JP7265537B2 (es) |
| KR (1) | KR20200105808A (es) |
| CN (1) | CN111542521B (es) |
| AU (1) | AU2018328818C1 (es) |
| BR (1) | BR112020004828A2 (es) |
| CA (1) | CA3075062A1 (es) |
| DK (1) | DK3681884T3 (es) |
| ES (1) | ES2925218T3 (es) |
| HU (1) | HUE059969T2 (es) |
| IL (2) | IL293332B2 (es) |
| MX (2) | MX2020002745A (es) |
| PH (1) | PH12020550079A1 (es) |
| PL (1) | PL3681884T3 (es) |
| PT (1) | PT3681884T (es) |
| SG (2) | SG11202002069WA (es) |
| SI (1) | SI3681884T1 (es) |
| TW (1) | TWI791608B (es) |
| WO (1) | WO2019051465A1 (es) |
| ZA (1) | ZA202104029B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019014315A1 (en) | 2017-07-11 | 2019-01-17 | Cyteir Therapeutics, Inc. | RAD51 INHIBITORS |
| JP7265537B2 (ja) * | 2017-09-11 | 2023-04-26 | サイティアー セラピューティクス，インコーポレイティド | Ｒａｄ５１阻害剤 |
| JP7460649B2 (ja) * | 2019-03-12 | 2024-04-02 | サイティアー セラピューティクス，インコーポレイティド | Ｒａｄ５１インヒビター |
| CA3133005A1 (en) * | 2019-03-25 | 2020-10-01 | Cyteir Therapeutics, Inc. | Combinations of rad51 and parp inhibitors |
| CA3143716A1 (en) * | 2019-06-21 | 2020-12-24 | Cyteir Therapeutics, Inc. | Methods of using rad51 inhibitors for treatment of pancreatic cancer |
| EP4108663A1 (en) | 2020-02-19 | 2022-12-28 | Simcere Pharmaceutical Co., Ltd. | Substituted aryl compound |
| AU2021231802A1 (en) * | 2020-03-03 | 2022-10-06 | Cyteir Therapeutics, Inc. | The RAD51 inhibitor Compound 67A (2301085-06-1) at a specific dosage for treating cancer |
| JP2022151436A (ja) * | 2021-03-26 | 2022-10-07 | 均 石井 | 髄膜炎と脳炎の治療薬。 |
| CN116063243A (zh) * | 2021-11-02 | 2023-05-05 | 上海旭成医药科技有限公司 | 芳香化合物、其制备方法、中间体、药物组合物和应用 |
| CN116196314B (zh) * | 2023-05-04 | 2023-08-15 | 广州市妇女儿童医疗中心 | Ri-1或其盐在制备防治胃肠道疾病的药物中的应用 |
| CN117603097A (zh) * | 2023-11-29 | 2024-02-27 | 安徽泽升科技股份有限公司 | 一种快速制备2-溴-5-硝基苯磺酰氯的方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014085545A1 (en) | 2012-11-30 | 2014-06-05 | The University Of Chicago | Methods and compositions involving rad51 inhibitors |
| WO2016140971A1 (en) | 2015-03-02 | 2016-09-09 | The Regents Of The University Of California | Novel rad51 inhibitors and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| WO1992010588A1 (en) | 1990-12-06 | 1992-06-25 | Affymax Technologies N.V. | Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US6309823B1 (en) | 1993-10-26 | 2001-10-30 | Affymetrix, Inc. | Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same |
| GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
| DK2099442T3 (en) | 2006-12-26 | 2015-02-16 | Pharmacyclics Inc | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
| CN102858767B (zh) | 2009-12-17 | 2015-08-19 | 默沙东公司 | 作为syk抑制剂的氨基嘧啶 |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| WO2016196955A1 (en) * | 2015-06-04 | 2016-12-08 | Drexel University | Inhibitors of RAD52 Recombination Protein and Methods Using Same |
| WO2019014315A1 (en) | 2017-07-11 | 2019-01-17 | Cyteir Therapeutics, Inc. | RAD51 INHIBITORS |
| JP7265537B2 (ja) | 2017-09-11 | 2023-04-26 | サイティアー セラピューティクス，インコーポレイティド | Ｒａｄ５１阻害剤 |
| JP7460649B2 (ja) | 2019-03-12 | 2024-04-02 | サイティアー セラピューティクス，インコーポレイティド | Ｒａｄ５１インヒビター |
| CA3133005A1 (en) * | 2019-03-25 | 2020-10-01 | Cyteir Therapeutics, Inc. | Combinations of rad51 and parp inhibitors |
-
2018
- 2018-09-11 JP JP2020514206A patent/JP7265537B2/ja active Active
- 2018-09-11 PT PT187822572T patent/PT3681884T/pt unknown
- 2018-09-11 EP EP18782257.2A patent/EP3681884B1/en active Active
- 2018-09-11 PL PL18782257.2T patent/PL3681884T3/pl unknown
- 2018-09-11 HU HUE18782257A patent/HUE059969T2/hu unknown
- 2018-09-11 DK DK18782257.2T patent/DK3681884T3/da active
- 2018-09-11 IL IL293332A patent/IL293332B2/en unknown
- 2018-09-11 KR KR1020207010585A patent/KR20200105808A/ko not_active Application Discontinuation
- 2018-09-11 AU AU2018328818A patent/AU2018328818C1/en active Active
- 2018-09-11 IL IL273156A patent/IL273156B/en unknown
- 2018-09-11 EP EP22175891.5A patent/EP4112616A1/en active Pending
- 2018-09-11 WO PCT/US2018/050391 patent/WO2019051465A1/en active Application Filing
- 2018-09-11 SG SG11202002069WA patent/SG11202002069WA/en unknown
- 2018-09-11 US US16/127,229 patent/US10590122B2/en active Active
- 2018-09-11 MX MX2020002745A patent/MX2020002745A/es unknown
- 2018-09-11 TW TW107131953A patent/TWI791608B/zh active
- 2018-09-11 BR BR112020004828-3A patent/BR112020004828A2/pt unknown
- 2018-09-11 SG SG10202107087YA patent/SG10202107087YA/en unknown
- 2018-09-11 SI SI201830740T patent/SI3681884T1/sl unknown
- 2018-09-11 CA CA3075062A patent/CA3075062A1/en active Pending
- 2018-09-11 ES ES18782257T patent/ES2925218T3/es active Active
- 2018-09-11 CN CN201880072664.5A patent/CN111542521B/zh active Active
- 2018-12-31 US US16/236,894 patent/US10336746B1/en active Active
-
2020
- 2020-01-06 US US16/734,566 patent/US11084812B2/en active Active
- 2020-03-06 PH PH12020550079A patent/PH12020550079A1/en unknown
- 2020-03-11 MX MX2023004221A patent/MX2023004221A/es unknown
-
2021
- 2021-06-11 ZA ZA2021/04029A patent/ZA202104029B/en unknown
- 2021-06-30 US US17/363,099 patent/US20220056022A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014085545A1 (en) | 2012-11-30 | 2014-06-05 | The University Of Chicago | Methods and compositions involving rad51 inhibitors |
| WO2016140971A1 (en) | 2015-03-02 | 2016-09-09 | The Regents Of The University Of California | Novel rad51 inhibitors and uses thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7265537B2 (ja) | Ｒａｄ５１阻害剤 | |
| JP2022537372A (ja) | 膵臓がんの治療にｒａｄ５１阻害剤を利用する方法 | |
| JP7460649B2 (ja) | Ｒａｄ５１インヒビター | |
| RU2795882C2 (ru) | Ингибиторы rad51 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210816 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210816 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220728 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220823 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221122 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230216 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230328 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230414 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7265537 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |